{
    "name": "inotersen",
    "comment": "Rx",
    "other_names": [
        "Tegsedi"
    ],
    "classes": [
        "Rheumatologics",
        "Antisense Oligonucleotides"
    ],
    "source": "https://reference.medscape.com/drug/tegsedi-inotersen-1000231",
    "pregnancy": {
        "common": [
            "There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to drug during pregnancy; health care providers are encouraged to register patients and pregnant women are encouraged to register themselves by calling: 1-877-465-7510, emailing: tegsedipregnancy@ubc.com, or visiting online at ",
            "There are no available data regarding use in pregnant women",
            "Inotersen treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised for patients taking inotersen; vitamin A is essential for normal embryofetal development; however, excessive levels of vitamin A are associated with adverse developmental effects",
            "Effects on the fetus of maternal serum transthyretin (TTR) reduction caused by inotersen and vitamin A supplementation are unknown"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In animal studies, SC administration of inotersen to pregnant rabbits resulted in premature delivery and reduced fetal body weight"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human milk",
            "The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Thrombocytopenia ",
                    "description": [
                        "Reductions in platelet count may result in sudden and unpredictable thrombocytopenia, which can be life-threatening",
                        "One clinical trial patient died from intracranial hemorrhage",
                        "Contraindicated in patients with a platelet count <100x 10^9/L",
                        "Obtain a platelet count before initiating drug",
                        "During treatment, monitor platelet counts weekly if values are ≥75x 10^9/L, and more frequently if values are <75x 10^9/L",
                        "If signs or symptoms of thrombocytopenia develop, obtain a platelet count as soon as possible; hold dosing until platelet count is determined to be interpretable and acceptable by a medical professional",
                        "Following discontinuation of treatment for any reason, continue to monitor platelet count for 8 weeks, or longer if platelet counts are <100x 10^9/L, to verify that platelet counts remain >75x 10^9/L"
                    ]
                },
                {
                    "type": "Glomerulonephritis ",
                    "description": [
                        "Inotersen can cause glomerulonephritis that may require immunosuppressive treatment and may result in dialysis-dependent renal failure",
                        "One clinical trial patient who developed glomerulonephritis and did not receive immunosuppressive treatment remained dialysis dependent",
                        "In clinical trials, cases of glomerulonephritis were accompanied by nephrotic syndrome, which can have manifestations of edema, hypercoagulability with venous or arterial thrombosis, and increased susceptibility to infection",
                        "Should generally not be initiated in patients with UPCR ≥1000 mg/g",
                        "Before initiating drug, measure serum creatinine, eGFR, UPCR, and perform urinalysis",
                        "During treatment, monitor serum creatinine, eGFR, urinalysis, and UPCR q2weeks",
                        "Do not administer to patients who develop UPCR ≥1000 mg/g or eGFR <45 mL/minute/1.73 m², pending further evaluation of the cause",
                        "If dose held, may reinitiate weekly dosing once eGFR increases to ≥45 mL/minute/1.73 m², UPCR decreases to <1000 mg/g, or the underlying cause of the decline in renal function is corrected",
                        "If UPCR ≥2000 mg/g, perform further evaluation for acute glomerulonephritis, as clinically indicated; if confirmed, permanently discontinue inotersen"
                    ]
                },
                {
                    "type": "REMS program ",
                    "description": [
                        "Owing to risks of serious bleeding caused by severe thrombocytopenia and glomerulonephritis, both of which require frequent monitoring, inotersen is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS)"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Platelet count <100x 10^9/L",
                "History of acute glomerulonephritis caused by inotersen",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Causes platelet count reduction that may result in sudden and unpredictable thrombocytopenia that can be life-threatening; monitoring required",
                "Uninterpretable platelet counts may occur owing to platelet clumping that occurs between antiplatelet antibodies and EDTA; if EDTA-mediated platelet clumping suspected, repeat platelet count using a different anticoagulant (eg, sodium citrate, heparin) in the blood collection tube",
                "Can cause glomerulonephritis that may result in dialysis-dependent renal failure; monitoring required; treatment for glomerulonephritis is immunosuppressive therapy; avoid use in patients for whom immunosuppressive treatment is not advised",
                "Prescribers must be certified to prescribe inotersen by enrolling in and completing the REMS training program; patients must enroll in the program and comply with ongoing monitoring requirements",
                "May cause stroke and cervicocephalic arterial dissection (rare) within 2 days of the first dose; patients may also have symptoms of cytokine release (eg, nausea, vomiting, muscular pain, weakness) and a high-sensitivity C-reactive protein level >100 mg/L during this time",
                "Vitamin A levels may decrease; supplementation with recommended daily allowance advised; refer to ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occurs (eg, night blindness)"
            ],
            "specific": [
                {
                    "type": "Inflammatory and immune effects",
                    "description": [
                        "May cause inflammatory and immune changes, including immune thrombocytopenia, glomerulonephritis, or rarely, antineutrophil cytoplasmic autoantibody (ANCA)-positive systemic vasculitis",
                        "One patient developed gait changes that progressed over 6 months to paraparesis, in the absence of radiologic evidence of spinal cord compression",
                        "Another patient developed progressive lumbar pain, weight loss, headache, vomiting, and impaired speech 7 months after starting inotersen; CSF analysis findings included elevated protein, lymphocyte-predominant pleocytosis, and testing that was negative for infection; recovery occurred after empiric therapy (ie, high-dose steroids, antibiotics) and the patient resumed inotersen without recurrence of symptoms",
                        "The liver accumulates antisense oligonucleotides; monitor ALT, AST, and total bilirubin",
                        "Cases of liver transplant rejection reported 2-4 months after starting therapy in patients whose liver allografts had previously been clinically stable (for over 10 years) prior to starting therapy; patients clinically improved and transaminase levels normalized after glucocorticoid administration and cessation of therapy; in patients with a history of liver transplant, monitor ALT, AST, and total bilirubin monthly; discontinue therapy in patients who develop signs of liver transplant rejection",
                        "Hypersensitivity may occur; discontinue treatment and do not reinitiate"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Owing to thrombocytopenia risk, caution if inotersen is coadministered with antiplatelets or anticoagulants",
                        "Caution if coadministered with other drugs that may impair renal function"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, inotersen.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "inotersen increases effects of warfarin by anticoagulation. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "49"
        },
        {
            "name": "Nausea",
            "percent": "31"
        },
        {
            "name": "Headache",
            "percent": "26"
        },
        {
            "name": "Fatigue",
            "percent": "25"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "24"
        },
        {
            "name": "Fever",
            "percent": "20"
        },
        {
            "name": "Peripheral edema",
            "percent": "19"
        },
        {
            "name": "Chills",
            "percent": "18"
        },
        {
            "name": "Anemia",
            "percent": "17"
        },
        {
            "name": "Vomiting",
            "percent": "15"
        },
        {
            "name": "Myalgia",
            "percent": "15"
        },
        {
            "name": "Decreased renal function",
            "percent": "14"
        },
        {
            "name": "Arrhythmia",
            "percent": "13"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "Presyncope or syncope",
            "percent": "13"
        },
        {
            "name": "Decreased appetite",
            "percent": "10"
        },
        {
            "name": "Paresthesia",
            "percent": "10"
        },
        {
            "name": "Dyspnea",
            "percent": "9"
        },
        {
            "name": "Elevated liver function test",
            "percent": "9"
        },
        {
            "name": "Orthostasis",
            "percent": "8"
        },
        {
            "name": "Influenzalike illness",
            "percent": "8"
        },
        {
            "name": "Contusion",
            "percent": "7"
        },
        {
            "name": "Bacterial infection",
            "percent": "7"
        },
        {
            "name": "Eosinophilia",
            "percent": "5"
        },
        {
            "name": "Dry mouth",
            "percent": "5"
        }
    ]
}